A translational clinical trial demonstrated that tumors with high-level clonal FGFR2 gene amplification showed response to treatment (four out of nine patients with FGFR2-amplified gastroesophageal cancer), although the sample size for the gastric cancer cohort was limited [66]. The gene discussed is FGFR2; the disease is gastric cancer.